Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H12Cl2N4O |
Molecular Weight | 359.209 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=NN=C2CN=C(C3=CC=CC=C3Cl)C4=CC(Cl)=CC=C4N12
InChI
InChIKey=BHUYWUDMVCLHND-UHFFFAOYSA-N
InChI=1S/C17H12Cl2N4O/c18-10-5-6-14-12(7-10)17(11-3-1-2-4-13(11)19)20-8-15-21-22-16(9-24)23(14)15/h1-7,24H,8-9H2
Molecular Formula | C17H12Cl2N4O |
Molecular Weight | 359.209 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
a-Hydroxytriazolam is a major urinary and blood metabolite of the benzodiazepine, triazolam, a pharmaceutical used to treat severe insomnia. It is suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research. Triazolam is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states. As triazolam has a relatively short half-life of about 2 to 3 hours in healthy subjects and has only 1 short acting active metabolite, alpha-hydroxytriazolam. a-Hydroxytriazolam is reported to have 50
to 100 % of the pharmacological activity of the
parent compound. Triazolam (marketed in English-speaking countries under the brand names Apo-Triazo, Halcion, Hypam, and Trilam) is a benzodiazepine drug. It possesses pharmacological properties similar to that of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties triazolam possesses, amnesic, anxiolytic, sedative, anticonvulsant and muscle relaxant properties are also present.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
0.8 nM [Ki] | ||
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
0.8 nM [Ki] | ||
Target ID: CHEMBL2094130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
0.59 nM [Ki] | ||
Target ID: CHEMBL2094120 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
1.43 nM [Ki] | ||
Target ID: CHEMBL2094122 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
1.54 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Halcion Approved UseHalcion is indicated for the short-term treatment of insomnia (generally 7–10 days). Use for more than 2–3 weeks requires complete reevaluation of the patient Launch Date1982 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6114852
Curator's Comment: a-Hydroxytriazolam is an active metabolite of triazolam
Usual hypnotic doses of triazolam 0.25 or 0.5 mg per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16198966
The incubation mixture contained triazolam (substrate concentration: 0–250
nM; therapeutic level 6–60 nM, toxic level 120 nM, fatal
level 200–300 nM) in a total volume of 0.5 ml. Incubations were carried out in microsomes from three pooled human livers t for 20 min in a shaking water-bath at 37 C.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:58:24 GMT 2023
by
admin
on
Sat Dec 16 13:58:24 GMT 2023
|
Record UNII |
J53Y2M2SAH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1963
Created by
admin on Sat Dec 16 13:58:24 GMT 2023 , Edited by admin on Sat Dec 16 13:58:24 GMT 2023
|
PRIMARY | |||
|
37115-45-0
Created by
admin on Sat Dec 16 13:58:24 GMT 2023 , Edited by admin on Sat Dec 16 13:58:24 GMT 2023
|
PRIMARY | |||
|
DTXSID50958284
Created by
admin on Sat Dec 16 13:58:24 GMT 2023 , Edited by admin on Sat Dec 16 13:58:24 GMT 2023
|
PRIMARY | |||
|
J53Y2M2SAH
Created by
admin on Sat Dec 16 13:58:24 GMT 2023 , Edited by admin on Sat Dec 16 13:58:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
Major urine metabolite (50-100% active)
URINE
|